This project has been archived.

PBPK Modeling White Paper Working Group (Author & Review Teams)

Formed in response to exchange with FDA.  The goal is to present industry best practices for PBPK modeling to serve as a reference for future PBPK modeling regulatory guidance.
General Opportunities for Successful & Impactful Application in Drug Development

• Increase in knowledge of the system (e.g. enzymes and transporters)

• Increased collaboration to advance capabilities (e.g. Orbito consortium on absorption)

• Rapidly improving software tools requires increasing level of expertise among preclinical, clinical & modeling & simulation


• PBPK modeling facilitates collaborative working within companies to deliver impactful decisions & optimize drug development

• PBPK modeling supports effective regulatory interactions

Milestones (information current as of April 2015)

March 10, 2014 - FDA Public Workshop : “Application of Physiologically-Based Pharmacokinetic Modeling To Support Dose Selection”

June 30, 2014 - ABPI and MHRA : “MISG New Technologies Forum on physiologically based pharmacokinetic (PBPK) modelling and simulation”

November 14, 2014 - IQ White paper accepted for publication.  Published as:
Jones, H. M. et al. (2015). "Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective." Clinical pharmacology & Therapeutics 97(3): 247-262.